<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://aminowire.news/news/2026/10/nsw-peptide-emergency-visits-retatrutide/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-10-19T19:11:46.000Z</news:publication_date>
      <news:title>NSW: 1,180 peptide-linked ER visits, most name retatrutide</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/10/lilly-drops-retatrutide-suits-texas-peptides-lone-star/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-10-19T19:11:46.000Z</news:publication_date>
      <news:title>Lilly drops two more retatrutide suits, both with prejudice</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/10/cspi-urges-fda-reject-pcac-peptide-votes/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-10-19</news:publication_date>
      <news:title>CSPI urges FDA to overrule advisers on six peptides</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/10/peptide-interim-access-policy-omb-review/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-10-19</news:publication_date>
      <news:title>Peptide access policy goes to White House review</news:title>
    </news:news>
  </url>
</urlset>
